A Study Of Artemisinin Combination Therapy Given At Delivery To Prevent Postpartum Malaria And To Young Infants To Treat Uncomplicated Malaria
Funder
National Health and Medical Research Council
Funding Amount
$788,850.00
Summary
The proposed studies will investigate the preventive value of a course of combination antimalarial treatment at delivery in pregnant women in malarial areas. The transfer of this treatment into breast milk and to the suckling infant will be investigated since this may protect the infant against malaria but also cause drug-related side-effects. These data will be used, with a study of combination treatment in infants with malaria, to optimise dose regimens in this vulnerable group.
Breastfeeding In Women With Polycystic Ovarian Syndrome, Gestational Diabetes, And Pre-existing Diabetes: Hormonal Physiology, Breastmilk Composition, Epidemiology And Patient Factors
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
Polycystic ovary syndrome and diabetes (pre-existing or gestational) are important conditions in pregnant women. I intend to explore (through major literature reviews and original research) how they influence the production and composition of breastmilk, how this differs from women without the conditions, and impacts on infant health. I also aim to examine reasons for lactation difficulties in these women, both from a hormonal (basic science) perspective and at a broader (population) level.
ELF5 Integrates Prolactin And Progestin Control Of Mammary Gland Development Via Regulation Of Progenitor Cells.
Funder
National Health and Medical Research Council
Funding Amount
$720,515.00
Summary
Elf5 may act as a master-regulator of mammary cell growth during pregnancy. We will demonstrate that Elf5 can replace the requirement for prolactin and progesterone to trigger mammary development and we will determine the stem or progenitor cells Elf5 acts on. Finally we will apply this knowledge to breast cancer cell lines to discover what role Elf5 plays in breast cancer. These experiments have the potential to establish Elf5 as a new therapeutic target for the treatment of breast cancer.